City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver
Metropolis Therapeutics’ lead RNA interference remedy may change into an alternative choice to blockbuster-selling anticoagulants. The corporate’s expertise for designing ...








